REGN$681.72
$685.76
Chart
Performance
Key Stats
AI REGN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyRegeneron Pharmaceuticals demonstrates strong fundamentals with robust profitability and a healthy balance sheet. The company is well-positioned within key therapeutic areas. Current technicals suggest some near-term headwinds, while thematic tailwinds are present but less pronounced than in some other biotech firms.
Thematic
Regeneron benefits from strong secular trends in biopharmaceuticals, particularly in areas like ophthalmology and immunology. The growing prevalence of chronic diseases and advancements in genetic medicine support its long-term growth prospects.
Fundamental
Regeneron exhibits strong profitability, solid revenue growth, and a healthy balance sheet with ample cash reserves. Its valuation metrics are reasonable given its growth and profitability profile.
Technical
The stock is trading below its 52-week high and shows mixed signals across various timeframes. While some moving averages indicate support, momentum indicators suggest potential for near-term weakness or consolidation.
| Factor | Score |
|---|---|
| Aging Population & Chronic Disease | 85 |
| Biotechnology Innovation | 70 |
| Healthcare Spending Trends | 65 |
| Partnerships and Collaborations | 80 |
| Factor | Score |
|---|---|
| Valuation | 80 |
| Profitability | 95 |
| Growth | 70 |
| Balance Sheet Health | 95 |
| Cash Flow | 90 |
| Dividend Yield | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 65 |
| Support & Resistance | 60 |
| Volume Analysis | 60 |
| Short-term Price Action | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Favorable Valuation Metrics
The Price-to-Earnings (P/E) ratio of 19.9 (TTM) and 17.1 (2024 est.) is competitive within the industry, suggesting potential undervaluation compared to its growth prospects.
Consistent Earnings Surprises
The company has a history of beating analyst EPS estimates, with positive surprises in the last four reported quarters (ranging from 6.57% to 25.22%), indicating strong operational execution.
Bearish Points (7)
High Quarterly P/E Ratio
The current quarterly P/E ratio of 83.1 (Q1 2025) is significantly elevated, suggesting potential overvaluation based on short-term earnings.
Recent Underperformance
The stock has seen a negative performance of -17.31% over the last 6 months and -47.51% over the last year, indicating significant investor sentiment shift or market headwinds.
Calendar
May 2025
20
Ex-Dividend Date
June 2025
6
Next Dividend Date
August 2025
1
Next Earnings Date
H: $9.45
A: $8.44
L: $4.25
H: 3.45B
A: 3.28B
L: 3.02B
Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Seasonals
Price Target
722.50 USD
The 39 analysts offering 1 year price forecasts for REGN have a max estimate of 940.00 and a min estimate of 504.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Strategic co-development and co-commercialization partner for key Regeneron drugs like Dupixent and Libtayo.
Weight: 95
Direct competitor in ophthalmology (e.g., Lucentis, Beovu vs. Eylea) and strong presence in oncology.
Weight: 90
Direct competitor in ophthalmology (e.g., Lucentis, Vabysmo vs. Eylea) and major oncology player.
Weight: 88
Major competitor in immunology and inflammation with leading drugs like Skyrizi and Rinvoq.